Are you over 18 and want to see adult content?
More Annotations
A complete backup of deathtalkproject.com
Are you over 18 and want to see adult content?
A complete backup of gatwickairport.com
Are you over 18 and want to see adult content?
A complete backup of foodlifeline.org
Are you over 18 and want to see adult content?
A complete backup of immobiliengriechenland.com
Are you over 18 and want to see adult content?
A complete backup of kyrieirving-shoes.us
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of protectionrelay.ir
Are you over 18 and want to see adult content?
A complete backup of donateacar2charity.com
Are you over 18 and want to see adult content?
A complete backup of budde-grabmale.de
Are you over 18 and want to see adult content?
A complete backup of erickmart13.wordpress.com
Are you over 18 and want to see adult content?
A complete backup of berkeleyfreeclinic.org
Are you over 18 and want to see adult content?
Text
world. 337.5.
OVERVIEW - CARB-X
CARB-X is investing up to $480 million in 2016-2022 into the research and development of new antibiotics, vaccines, rapid diagnostics and other life-saving products to tackle the global threat of drug-resistant bacteria. CARB-X was created in response to the US government’s 2015 Combating Antibiotic Resistant Bacteria (CARB)initiative, and
CARB-X COMPLETE PORTFOLIO, AS OF 5/10/21 Integrated Biotherapeutics IBT-V02 Multi-valent vaccine S. aureus GlaxoSmithKline GSK iNTS-TCV iNTS-typhoid conjugate vaccine Salmonella enterica GlaxoSmithKline GSK Strep A vaccine Group A Streptococcus Vedanta VE707 Microbiome CRE - ESBLs Seres SER-155.ADVISORY BOARD
Supporting great science Outstanding experts make up CARB-X’s Advisory Boards, which include both a pre-award Advisory Board that reviews proposals and a post-award Advisory Board that reviews milestone achievement and Option plans. The Advisory Board ensures the highest scientific standards in evaluating applications for CARB-X funding. Every member of the CARB-X Advisory Board completes aBOSTON UNIVERSITY
Boston University is the home of CARB-X and at the heart of its operations. CARB-X is not a separate legal entity, but is fully a part of the University’s non-profit research mission. CARB-X is funded by the US Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust, Germany’s Federal Ministry of Education and Research (BMBF), the UK Government’s Global CARB-X IS FUNDING GSK TO SUPPORT THE DEVELOPMENT OF TWO GSK vaccines in pre-clinical development for the prevention of bacterial infections caused by Group A Streptococcus and Salmonella enterica (BOSTON) – CARB-X is funding the GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH), based in Siena, Italy, to develop new vaccines to prevent serious infections caused by two different pathogens. Together,ERIN DUFFY, PHD
Erin Duffy, Ph. D., comes to CARB-X with 17+ years of drug-discovery and problem-solving experience in the antibiotic arena. She joined then Rib-X Pharmaceuticals (now Melinta Therapeutics) as it was nucleating in New Haven, Connecticut, where in increasing roles she helped to build and sustain a team of researchers that translated the company’s scientific platformSNIPR BIOME APS
SNIPR BIOME ApS, Copenhagen, Denmark www.sniprbiome.com SNIPR001 CRISPR-ENGINEERED PRECISION PREVENTATIVE Escherichia coli (E. coli) in cancer patients SNIPR BIOME is developing a new precision therapy that would target E. coli bacteria in cancer patients with hematological malignancies, without harming beneficial bacteria in the microbiome. SNIPR’s new lead candidate drug, SNIPR001, CARB-X IS FUNDING THE UNIVERSITY OF QUEENSLAND TO DEVELOP UQ’s innovative Octapeptin drug would disable the bacteria’s protective wall, creating a path for antibiotics to enter the bacteria and kill them (BOSTON) – CARB-X is awarding up to US$2.2 million to The University of Queensland’s (UQ) Institute for Molecular Bioscience (IMB), Brisbane, Australia, to expand its Octapeptin research program to develop a new drugRICHARD ALM, PHD
Richard joined CARB-X following almost 20 years in large pharma infection R&D teams followed by 4 years at a small antibacterial biotech company. He has supported the progression of small molecule compounds from discovery through to late-stage clinical development. He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining HOME - CARB-XABOUT CARB-XPORTFOLIOPARTNERSAPPLYRESOURCESNEWS Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $337.5 million in 90 projects around theworld. 337.5.
OVERVIEW - CARB-X
CARB-X is investing up to $480 million in 2016-2022 into the research and development of new antibiotics, vaccines, rapid diagnostics and other life-saving products to tackle the global threat of drug-resistant bacteria. CARB-X was created in response to the US government’s 2015 Combating Antibiotic Resistant Bacteria (CARB)initiative, and
CARB-X COMPLETE PORTFOLIO, AS OF 5/10/21 Integrated Biotherapeutics IBT-V02 Multi-valent vaccine S. aureus GlaxoSmithKline GSK iNTS-TCV iNTS-typhoid conjugate vaccine Salmonella enterica GlaxoSmithKline GSK Strep A vaccine Group A Streptococcus Vedanta VE707 Microbiome CRE - ESBLs Seres SER-155.ADVISORY BOARD
Supporting great science Outstanding experts make up CARB-X’s Advisory Boards, which include both a pre-award Advisory Board that reviews proposals and a post-award Advisory Board that reviews milestone achievement and Option plans. The Advisory Board ensures the highest scientific standards in evaluating applications for CARB-X funding. Every member of the CARB-X Advisory Board completes aBOSTON UNIVERSITY
Boston University is the home of CARB-X and at the heart of its operations. CARB-X is not a separate legal entity, but is fully a part of the University’s non-profit research mission. CARB-X is funded by the US Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust, Germany’s Federal Ministry of Education and Research (BMBF), the UK Government’s Global CARB-X IS FUNDING GSK TO SUPPORT THE DEVELOPMENT OF TWO GSK vaccines in pre-clinical development for the prevention of bacterial infections caused by Group A Streptococcus and Salmonella enterica (BOSTON) – CARB-X is funding the GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH), based in Siena, Italy, to develop new vaccines to prevent serious infections caused by two different pathogens. Together,ERIN DUFFY, PHD
Erin Duffy, Ph. D., comes to CARB-X with 17+ years of drug-discovery and problem-solving experience in the antibiotic arena. She joined then Rib-X Pharmaceuticals (now Melinta Therapeutics) as it was nucleating in New Haven, Connecticut, where in increasing roles she helped to build and sustain a team of researchers that translated the company’s scientific platformSNIPR BIOME APS
SNIPR BIOME ApS, Copenhagen, Denmark www.sniprbiome.com SNIPR001 CRISPR-ENGINEERED PRECISION PREVENTATIVE Escherichia coli (E. coli) in cancer patients SNIPR BIOME is developing a new precision therapy that would target E. coli bacteria in cancer patients with hematological malignancies, without harming beneficial bacteria in the microbiome. SNIPR’s new lead candidate drug, SNIPR001, CARB-X IS FUNDING THE UNIVERSITY OF QUEENSLAND TO DEVELOP UQ’s innovative Octapeptin drug would disable the bacteria’s protective wall, creating a path for antibiotics to enter the bacteria and kill them (BOSTON) – CARB-X is awarding up to US$2.2 million to The University of Queensland’s (UQ) Institute for Molecular Bioscience (IMB), Brisbane, Australia, to expand its Octapeptin research program to develop a new drugRICHARD ALM, PHD
Richard joined CARB-X following almost 20 years in large pharma infection R&D teams followed by 4 years at a small antibacterial biotech company. He has supported the progression of small molecule compounds from discovery through to late-stage clinical development. He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joiningCARB-X NEWS
04.06.2021 | CARB-X is funding Novel Microdevices to develop a rapid and portable diagnostic for sexually transmitted diseases including antibiotic-resistant infections. CARB-X is awarding Novel Microdevices, Inc. of Baltimore, Maryland, USA, up to $3.6 million in non-dilutive funding, and, subject to available funding, up to anadditional $10
PUBLICATIONS
08.01.2015 | Antibiotic Resistance: Journal of American Society of Law, Medicine & Ethics Download. 06.01.2015 | Responding to the Threat of Antimicrobial Resistance Download. 02.26.2015 | Repairing the Broken Market for Antibiotic Innovation Download. 02.01.2015 | An international legal framework to address antimicrobial resistanceDownload.
PORTFOLIO-PRODUCT DEVELOPERS The CARB-X portfolio is the world’s largest and most diverse portfolio of early development antibacterial projects. CARB-X provides non-dilutive funding and expertise to support the early development of antibiotics, vaccines, rapid diagnostics and other life-saving products. CARB-X supports therapeutics through the early developmentphases
WORLD ANTIMICROBIAL RESISTANCE CONGRESS 2021 Antimicrobial resistance (AMR) is one of the biggest global health crises facing the world today. The number of deaths attributed to AMR is expected to surpass the number of deaths from cancer worldwide by 2050. Yet combatting resistance globally and developing a robust arsenal of antibiotics continues to fall behind the pace ofresistance. Since
RICHARD ALM, PHD
Richard joined CARB-X following almost 20 years in large pharma infection R&D teams followed by 4 years at a small antibacterial biotech company. He has supported the progression of small molecule compounds from discovery through to late-stage clinical development. He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining CARB-X STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENT OF Erin Duffy to lead the growth and oversight of CARB-X’s portfolio of antibiotics, diagnostics, vaccines and other life-saving products addressing antibacterial resistance on a global level (Boston, MA) – CARB-X, a global partnership led by Boston University, today announced the appointment of Erin Duffy, PhD, as Chief of Research and Development (R&D). Dr. Duffy will CARB-X IS FUNDING UK-BIOTECH GENOMEKEY TO DEVELOP A RAPID Innovative technology combines DNA extraction and sequencing with machine learning DNA interpretation (BOSTON) – CARB-X is awarding GenomeKey (Genomics Labs Ltd.) in Bristol, UK, up to $3.0 million in non-dilutive funding to develop an innovative rapid diagnostic for sepsis. GenomeKey is eligible for up to $6.5 million in additional awards if the project achieves certainMANAGEMENT & STAFF
Tina Mercado-Bradford, MBA. Finance and Grants Manager. Full Profile. Alexandra Regan, MPH. Communications and Administrative Specialist CARB-X IS FUNDING BASILEA PHARMACEUTICA TO DEVELOP A NEW Basilea’s new drug targets drug-resistant bacteria identified by the World Health Organization (WHO) as ‘critical’ pathogens against which new antibiotics are urgently needed (BOSTON) – CARB-X is awarding Basilea Pharmaceutica International (SIX: BSLN), Basel, Switzerland, up to US $2.7 million to develop a novel class of antibiotics to treat Gram-negative bacterial infections. Gram CARB-X FUNDS CONTRAFECT TO DEVELOP A NEW CLASS OF ContraFect’s new class of phage-encoded lytic agents called ‘amurins’ aims to treat the deadliest drug-resistant Gram-negative pathogens (BOSTON, MA) – CARB-X is awarding ContraFect Corporation (Nasdaq:CFRX) of Yonkers, New York, USA, up to $1.75 million in non-dilutive funding with the possibility of $5.19 million more if certain project milestones are met, to develop novel HOME - CARB-XABOUT CARB-XPORTFOLIOPARTNERSAPPLYRESOURCESNEWS Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $337.5 million in 90 projects around theworld. 337.5.
OVERVIEW - CARB-X
CARB-X is investing up to $480 million in 2016-2022 into the research and development of new antibiotics, vaccines, rapid diagnostics and other life-saving products to tackle the global threat of drug-resistant bacteria. CARB-X was created in response to the US government’s 2015 Combating Antibiotic Resistant Bacteria (CARB)initiative, and
CARB-X COMPLETE PORTFOLIO, AS OF 5/10/21 Integrated Biotherapeutics IBT-V02 Multi-valent vaccine S. aureus GlaxoSmithKline GSK iNTS-TCV iNTS-typhoid conjugate vaccine Salmonella enterica GlaxoSmithKline GSK Strep A vaccine Group A Streptococcus Vedanta VE707 Microbiome CRE - ESBLs Seres SER-155.RICHARD ALM, PHD
Richard joined CARB-X following almost 20 years in large pharma infection R&D teams followed by 4 years at a small antibacterial biotech company. He has supported the progression of small molecule compounds from discovery through to late-stage clinical development. He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining WORLD ANTIMICROBIAL RESISTANCE CONGRESS 2021 Antimicrobial resistance (AMR) is one of the biggest global health crises facing the world today. The number of deaths attributed to AMR is expected to surpass the number of deaths from cancer worldwide by 2050. Yet combatting resistance globally and developing a robust arsenal of antibiotics continues to fall behind the pace ofresistance. Since
BOSTON UNIVERSITY
Boston University is the home of CARB-X and at the heart of its operations. CARB-X is not a separate legal entity, but is fully a part of the University’s non-profit research mission. CARB-X is funded by the US Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust, Germany’s Federal Ministry of Education and Research (BMBF), the UK Government’s Global ED BUURMAN, PHD, MBA Ed spent more than 20 years in large pharma (Pfizer, AstraZeneca) and biotech (Scriptgen/Anadys Pharmaceuticals), focussing on both therapeutic and preventive approaches to infections caused by viruses, bacteria and fungi. Over the years his responsibilities increased from bench scientist to research project lead and alliance director. He earned his PhD in Microbiology at the UniversityERIN DUFFY, PHD
Erin Duffy, Ph. D., comes to CARB-X with 17+ years of drug-discovery and problem-solving experience in the antibiotic arena. She joined then Rib-X Pharmaceuticals (now Melinta Therapeutics) as it was nucleating in New Haven, Connecticut, where in increasing roles she helped to build and sustain a team of researchers that translated the company’s scientific platform PADMINI SRIKANTIAH, MD MPH Padmini Srikantiah is a Senior Program Officer in Global Health at the Bill & Melinda Gates Foundation. In her role, she leads the foundation’s cross-cutting Antimicrobial Resistance (AMR) strategy with a focus on preventing drug resistant infections in vulnerable populations. Previously, Padmini was with the U.S. Centers for Disease Control and Prevention as a SeniorNADIA COHEN, PHD
Nadia brings over a decade of experience in Immunology and Microbiology from both Academia and Industry. Passionate about translational infectious disease research, Nadia joined CARB-X in 2016 from a Senior Scientist position at Moderna Therapeutics’ fledgling Vaccine development unit where she initiated and lead an anti-bacterial vaccine group for several years. Prior to that,Nadia’s
HOME - CARB-XABOUT CARB-XPORTFOLIOPARTNERSAPPLYRESOURCESNEWS Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $337.5 million in 90 projects around theworld. 337.5.
OVERVIEW - CARB-X
CARB-X is investing up to $480 million in 2016-2022 into the research and development of new antibiotics, vaccines, rapid diagnostics and other life-saving products to tackle the global threat of drug-resistant bacteria. CARB-X was created in response to the US government’s 2015 Combating Antibiotic Resistant Bacteria (CARB)initiative, and
CARB-X COMPLETE PORTFOLIO, AS OF 5/10/21 Integrated Biotherapeutics IBT-V02 Multi-valent vaccine S. aureus GlaxoSmithKline GSK iNTS-TCV iNTS-typhoid conjugate vaccine Salmonella enterica GlaxoSmithKline GSK Strep A vaccine Group A Streptococcus Vedanta VE707 Microbiome CRE - ESBLs Seres SER-155.RICHARD ALM, PHD
Richard joined CARB-X following almost 20 years in large pharma infection R&D teams followed by 4 years at a small antibacterial biotech company. He has supported the progression of small molecule compounds from discovery through to late-stage clinical development. He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining WORLD ANTIMICROBIAL RESISTANCE CONGRESS 2021 Antimicrobial resistance (AMR) is one of the biggest global health crises facing the world today. The number of deaths attributed to AMR is expected to surpass the number of deaths from cancer worldwide by 2050. Yet combatting resistance globally and developing a robust arsenal of antibiotics continues to fall behind the pace ofresistance. Since
BOSTON UNIVERSITY
Boston University is the home of CARB-X and at the heart of its operations. CARB-X is not a separate legal entity, but is fully a part of the University’s non-profit research mission. CARB-X is funded by the US Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust, Germany’s Federal Ministry of Education and Research (BMBF), the UK Government’s Global ED BUURMAN, PHD, MBA Ed spent more than 20 years in large pharma (Pfizer, AstraZeneca) and biotech (Scriptgen/Anadys Pharmaceuticals), focussing on both therapeutic and preventive approaches to infections caused by viruses, bacteria and fungi. Over the years his responsibilities increased from bench scientist to research project lead and alliance director. He earned his PhD in Microbiology at the UniversityERIN DUFFY, PHD
Erin Duffy, Ph. D., comes to CARB-X with 17+ years of drug-discovery and problem-solving experience in the antibiotic arena. She joined then Rib-X Pharmaceuticals (now Melinta Therapeutics) as it was nucleating in New Haven, Connecticut, where in increasing roles she helped to build and sustain a team of researchers that translated the company’s scientific platform PADMINI SRIKANTIAH, MD MPH Padmini Srikantiah is a Senior Program Officer in Global Health at the Bill & Melinda Gates Foundation. In her role, she leads the foundation’s cross-cutting Antimicrobial Resistance (AMR) strategy with a focus on preventing drug resistant infections in vulnerable populations. Previously, Padmini was with the U.S. Centers for Disease Control and Prevention as a SeniorNADIA COHEN, PHD
Nadia brings over a decade of experience in Immunology and Microbiology from both Academia and Industry. Passionate about translational infectious disease research, Nadia joined CARB-X in 2016 from a Senior Scientist position at Moderna Therapeutics’ fledgling Vaccine development unit where she initiated and lead an anti-bacterial vaccine group for several years. Prior to that,Nadia’s
OVERVIEW - CARB-X
CARB-X is investing up to $480 million in 2016-2022 into the research and development of new antibiotics, vaccines, rapid diagnostics and other life-saving products to tackle the global threat of drug-resistant bacteria. CARB-X was created in response to the US government’s 2015 Combating Antibiotic Resistant Bacteria (CARB)initiative, and
PUBLICATIONS
08.01.2015 | Antibiotic Resistance: Journal of American Society of Law, Medicine & Ethics Download. 06.01.2015 | Responding to the Threat of Antimicrobial Resistance Download. 02.26.2015 | Repairing the Broken Market for Antibiotic Innovation Download. 02.01.2015 | An international legal framework to address antimicrobial resistanceDownload.
ADVISORY BOARD
Supporting great science Outstanding experts make up CARB-X’s Advisory Boards, which include both a pre-award Advisory Board that reviews proposals and a post-award Advisory Board that reviews milestone achievement and Option plans. The Advisory Board ensures the highest scientific standards in evaluating applications for CARB-X funding. Every member of the CARB-X Advisory Board completes a CARB-X IS FUNDING ACCELERATE DIAGNOSTICS TO DEVELOP A Accelerate’s novel optical imaging technology aims to rapidly identify infectious microbes to help clinicians speed treatment of patients with sepsis or at risk for sepsis (BOSTON) – CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. ANTI-INFECTIVES DRUG DEVELOPMENT SUMMIT Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments, biopharma, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance. With some now CARB-X STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENT OF Erin Duffy to lead the growth and oversight of CARB-X’s portfolio of antibiotics, diagnostics, vaccines and other life-saving products addressing antibacterial resistance on a global level (Boston, MA) – CARB-X, a global partnership led by Boston University, today announced the appointment of Erin Duffy, PhD, as Chief of Research and Development (R&D). Dr. Duffy will KEVIN OUTTERSON, ESQ. KEVIN OUTTERSON, ESQ. Executive Director. Kevin Outterson is a global thought leader on business models for antibiotic development and use. He is Professor of Law and N. Neil Pike Scholar of Health and Disability Law at Boston University School of Law, where heNADIA COHEN, PHD
Nadia Cohen, PHD Alliance Manager. Nadia brings over a decade of experience in Immunology and Microbiology from both Academia and Industry. Passionate about translational infectious disease research, Nadia joined CARB-X in 2016 from a Senior Scientist position at Moderna Therapeutics’ fledgling Vaccine development unit where she initiated and lead an anti-bacterial vaccine group forANN E. EAKIN, PHD
Ann Eakin is a Senior Scientific Officer in the Office of Biodefense, Research Resources & Translational Research in the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Dr. Eakin joined NIAID in 2013 as a therapeuticsspecialist in the
ANDREA SPELBERG
Andrea Spelberg is head of division for global health research at the German Federal Ministry of Education and Research (BMBF) and responsible for pharmaceutical and global health research. She joined the ministry in 2002, and from 2009 to 2017 served as head of division for higher education policy. Prior to joining the ministry, she workedSkip to content
Toggle navigation
* Contact
Search
Search
* About CARB-X
* Overview
* Global Threat
* Our Strategy
* Management & Staff * Joint Oversight Committee* Advisory Board
* Careers
* Annual Reports
* Boston University
* Portfolio
* Gallery
* Science Spotlight
* Graduates
* Partners
* Funding Partners
* Accelerators / Other Partners* Apply
* Before You Apply
* What CARB-X Funds
* Official Development Assistance * Research Compliance * Additional Information and Resources* Resources
* Presentations
* Videos
* Publications
* Education
* News
* CARB-X News
* In the News
* Antibiotic Resistance* Media Resources
* Events
* About CARB-X
* Overview
* Global Threat
* Our Strategy
* Management & Staff * Joint Oversight Committee* Advisory Board
* Careers
* Annual Reports
* Boston University
* Portfolio
* Gallery
* Science Spotlight
* Graduates
* Partners
* Funding Partners
* Accelerators / Other Partners* Apply
* Before You Apply
* What CARB-X Funds
* Official Development Assistance * Research Compliance * Additional Information and Resources* Resources
* Presentations
* Videos
* Publications
* Education
* News
* CARB-X News
* In the News
* Antibiotic Resistance* Media Resources
* Events
* Contact
* Legal
WINNING THE RACE AGAINST SUPERBUGSGROWING RESISTANCE
Antibiotic resistance is growing and we are running out of treatmentoptions.
WINNING THE RACE AGAINST SUPERBUGSA GLOBAL APPROACH
CARB-X is fundamentally reshaping the way antibacterial innovation is funded and supported around the world. WINNING THE RACE AGAINST SUPERBUGSINNOVATIVE SCIENCE
The companies funded by CARB-X represent some of the best and most innovative science in the fight against drug-resistant bacteria. WINNING THE RACE AGAINST SUPERBUGSPROTECTING MEDICINE
Many advances in modern medicine are dependent on the ability to fight infections with antibiotics. WINNING THE RACE AGAINST SUPERBUGS BACTERIA KNOW NO BOUNDARIES Drug-resistant bacteria are a threat to everyone, rich or poor, no matter where we live.HOME
------------------------- COVID-19: CARB-X REMAINS OPEN FOR BUSINESS – VIRTUALLY CARB-X STAFF MEMBERS ARE WORKING FROM HOME. WE CONTINUE TO MAKE PAYMENTS TO SUPPORT THE RESEARCH PROGRAMS IN OUR PORTFOLIO, AND WILL ANNOUNCE NEW AWARDS AS THEY ARE APPROVED AND CONTRACTS FINALIZED. EVEN AS WE COPE WITH THE COVID-19 PANDEMIC, IT IS CRITICAL THAT WE CONTINUE TO SUPPORT THE DEVELOPMENT OF INNOVATIVE ANTIBIOTICS AND OTHER THERAPEUTICS, VACCINES AND DIAGNOSTICS TO ADDRESS DRUG-RESISTANTBACTERIA.
------------------------- CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $222.06 million in 61 projects around the world.222.06
$million
Invested
61
innovative
Projects
7
different
Countries
15
focused on new classesPipeline
THE CHALLENGE
Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.Learn More
SPOTLIGHT ON SCIENCE T2 Biosystems’ diagnostic panel can identify superbug drug resistance days faster than current methodsLearn More
“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.” — Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.FUNDERS
ALLIANCE PARTNERS
ACCELERATORS AND OTHER PARTNERSEVENTS
05.28.20
Boston, MA
LIVE WEBINAR – CARB-X - HOW TO PREPARE FOR AN FDA PRE-IND MEETING: PLANNING FOR SUCCESSMore
06.09.20
Boston, MA
LIVE WEBINAR: GARDP/REVIVE – TEST TUBE TO PATIENT: PK/PD OF FIXED DOSE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONSMore
06.30.20
Boston, MA
LIVE WEBINAR: GARDP/REVIVE – CLINICAL DEVELOPMENT OF ANTIMICROBIALS – PHASE 1 DEVELOPMENT CHALLENGESMore
NEWS
*
05.18.2020 | CARB-X funds Facile Therapeutics to develop a new treatment to prevent recurring C. difficile bacterial infections fullrelease
*
05.11.2020 | CARB-X funds 60th project – $220M invested so far, plus millions more if milestones are met full release*
05.11.2020 | CARB-X awards Day Zero Diagnostics $6.2M to develop a new test that would diagnose deadly superbug infections faster and determine what antibiotic would be most effective full releaseSee All News
IN THE NEWS
*
05.05.2020 | Antibiotic pipeline in peril from coronavirus and incentives system full story*
05.05.2020 | Coronavirus lessons for the fight against ‘superbugs’ full story*
04.29.2020 | Is AMR the next, but hidden, crisis? full storySee All News
SIGN UP FOR CARB-X NEWS Get the latest news and announcements from CARB-X.Email Address
Led by Boston UniversityCopyright 2020
* Contact
* Site Credits
* Legal
Copyright 2020
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0